Sarepta Therapeutics (SRPT) Tops Q4 EPS by 4c, Beats on Revenues
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Sarepta Therapeutics (SRPT) PT Raised to $96 at Nomura/Instinet on 4Q Beat; 'Pipeline Registration Path & DMD Gene Therapies Emerge in 2018'
March 2, 2018 6:21 AM ESTNomura/Instinet raised its price target on Sarepta Therapeutics (NASDAQ: SRPT) to $96.00 (from $84.00) while maintaining a Buy rating, following the company's fourth quarter earnings report.
Analyst Christopher Marai notes a positive outlook on the shares, as SRPT reported fourth quarter earning per share and... More
